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Abstract
Mutations in the Bruton agammaglobulinemia tyrosine kinase (BTK) gene are
responsible for X-linked agammaglobulinemia (XLA). Unfolded or misfolded
proteins can trigger stress pathways in the endoplasmic reticulum (ER), known as
unfolded protein response (UPR). The aim was to clarify the involvement of UPR
in XLA pathophysiology. By reverse transcription-quantitative PCR, we evaluated
the expression of BTK and 12 UPR-related genes in eight patients. Moreover, we
assessed the BTK protein expression and pattern in the patients’ monocytes by flow
cytometry and fluorescence immunocytochemistry. We found a reduced BTK
expression in patients with stop codon mutations (P< 0.02). However, missense
mutations did not affect BTK expression. Flow cytometry showed a reduction of
BTK in patients which was corroborated by an absent or nonfunctional protein
synthesis revealed by immunocytochemistry. In contrast with the other UPR-
related genes, X-box binding protein 1 (XBP1) was markedly upregulated in the
patients (P< 0.01), suggesting Toll-like receptor (TLR) activation since BTK
directly interacts with TLRs as a negative regulator and XBP1 can be activated in
direct response to TLR ligation. Different BTK mutations can be identified by the
BTK expression. Inasmuch as UPR-related genes were downregulated or unaltered
in patients, we speculate the involvement of the TLRs-XBP1 axis in the XLA
pathophysiology. Such data could be the basis for further studies of this novel
pathomechanism concerning XLA.
Introduction
X-linked agammaglobulinemia (XLA, OMIM # 300755) is
characterized by an end in differentiation of B lymphocytes
in bone marrow, leading to profound hypogammaglobuli-
nemia, few or absent peripheral B lymphocytes, and
recurrent infections with encapsulated bacteria and enter-
oviruses [1, 2]. Bruton agammaglobulinemia tyrosine kinase
(BTK) is the gene which causes XLA when functionally
mutated [3, 4]. It encompasses 37.5 kb containing 19 exons
and encodes a multidomain protein composed of five
different domains [4, 5].
Mutations have been found in all BTK domains, being
spread throughout the gene (http://bioinf.uta.fi/BTKbase)
and have been reported in many different countries [6]. Our
group has been the first to publish the diagnosis of XLA by
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analysis of mutations of the BTK gene in Brazilian patients
[7, 8]. Despite the large number of mutations identified, it
has not been possible to correlate the genetic defect with the
severity of the resulting clinical phenotype [9]. Expression
analyses in XLA patients have shown that most of these
individuals do not express BTK protein regardless of the
mutations they have [10–13]. However, it is not clear how
specific mutations may affect the function of BTK and cause
XLA.
Unfolded or misfolded proteins can trigger stress path-
ways in the endoplasmic reticulum (ER), called unfolded
protein response (UPR). Stress pathways of the ER have been
implicated in inflammatory diseases [14] but not yet studied
in XLA patients. There are three ER stress branches of
sensors: ERN1 (endoplasmic reticulum to nucleus signaling
1) (also known as IRE1 [inositol-requiring protein 1]),
EIF2AK3 (eukaryotic translation initiation factor 2-alpha
kinase 3) (also known as PERK [PKR-like-ER kinase]), and
ATF6 (activating transcription factor 6). The ERN1-XBP1
(X-box binding protein 1) pathway is the most highly
conserved and is critical for ER biogenesis and the secretory
capacity of cells [15].
The amount of XBP1 mRNA is critical to the production
of the active (spliced) form of (s)XBP1 [16]; the XBP1
mRNA level is kept low in non-stressed cells and its
transcription is induced under ER stress [17]. As UPR is
constitutively active at a basal level [18–20], regulation
through induction or repression of XBP expression allows
the maintenance of ER homeostasis [15]. Moreover, XBP1
activity is regulated at multiple levels and may modulate ER
homeostasis independently of classic UPR activation [15].
Studies demonstrated that XBP1 plays a role in innate and
adaptive immune responses such as in the terminal
differentiation of B lymphocytes to plasma cells [21],
effector CD8þ T cells [22], in dendritic cell survival [23],
immunoglobulin secretion [24], and macrophage responses
induced via Toll-like receptors [25].
In this study, we investigated the relation between the
mutated BTK and UPR and report for the first time the
overexpression of XBP1 in monocytes from XLA patients. As
an important multifunctional transcription factor that
controls the expression of critical genes associated with
the proper functioning of the immune system and the
cellular stress response, the involvement of XBP1 on the XLA
pathophysiology is conceivable.
Methods
Subjects
X-linked agammaglobulinemia was diagnosed according to
the criteria of the World Health Organization scientific
group for primary immunodeficiency diseases [26]: low
levels of circulating B cells (measured by levels of CD19-
positive cells in blood samples), decreased or absent
immunoglobulins in serum, and a typical clinical history
with recurrent bacterial infection or a positive family history.
Eight male patients with X-linked agammaglobulinemia
(median age 17.73; range from 6.36 to 32.02 years old) and
eight healthy male volunteers (median age 18.62; range from
6.39 to 32.45 years old) were enrolled for the study. Patients
were in a clinically stable situation without fever and not
hospitalized. They were under intravenous human immu-
noglobulin therapy monthly and had no infectious
intercurrences.
Monocyte UPR-related gene expression evaluations were
carried out only in six patients (median age 14.36; range
from 6.36 to 32.02) because two could not provide an
adequate amount of cells. For statistical comparisons, the
control group also consisted of six age- and gender-matched
healthy volunteers.
This study was approved by the Research Ethics
Committee of the University of Campinas (UNICAMP),
Campinas, S~ao Paulo, Brazil (#759/2005). Clinical character-
istics, including levels of immunoglobulins and B cell
number, are described in Table 1.
Detection of BTK mutations
Briefly, peripheral blood mononuclear cells (PBMC) were
prepared from venous blood using Ficoll-Hypaque separa-
tion. Total RNA was extracted from PBMC with TRIzol
1
Reagent (Life Technologies, Carlsbad, CA) and used for first-
strand cDNA synthesis. Bruton agammaglobulinemia tyro-
sine kinase PCR amplifications involved seven overlapping
primers [10]. To confirm the detected mutation, genomic
DNA was purified from venous blood with a Gentra
Puregene Blood Kit (QIAGEN, Life Technologies) and
amplified with primers encompassing the changed region in
the BTK gene [27]. Amplicons were sequenced by an ABI
3730 DNA Analyzer (Life Technologies).
Reverse transcription-quantitative PCR (RT-qPCR)
To extract total RNA, 1mL of TRIzol
1
Reagent (Life
Technologies) was added per 5–10 106 of PBMC samples,
homogenized, and then further processed according to the
manufacturer’s instructions. Subsequently, 1mg of total
RNA of each sample was reverse transcribed into cDNA
using 200U of Superscript III Reverse Transcriptase (Life
Technologies) and 3mg of Random Primers (Life Technol-
ogies) again according to the manufacturer’s instructions.
To assess the expression of ER stress sensors on monocytes,
CD14þ monocyte subpopulation was isolated from PBMC
using a magnetic cell sorting system in accordance with the
manufacturer’s protocol (Miltenyi Biotec, Bergisch
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Gladbach, Germany). Total RNA was extracted from
monocytes with an illustra RNAspin Mini Isolation kit
(GE Healthcare, Buckinghamshire, UK) and similarly
reverse transcribed into cDNA.
Complementary DNA samples derived from the investi-
gated genes (Table 2) were detected using an ABI PRISM
7500 Sequence Detection System (Life Technologies) and
TaqMan Gene Expression Assays (Life Technologies): 50-
FAM-labeled probes and corresponding primer pairs.
Each qPCR was run as triplicates with a cDNA sample of
10 ng in 6.25mL of TaqMan Gene Expression Master Mix
(Life Technologies), 0.625mL of the respective probe/primer
mix, and 0.625mL of purified and deionized H2O. Relative
gene expression quantification data were generated and
analyzed using the 7500 Software version 2.0.5 (Life
Technologies). Expression levels of genes were calculated
with the 2DDCt method using the combination of GAPDH
and HPRT1 as the reference gene.
Flow cytometry analysis of BTK expression
BTK protein quantification was calculated by flow cytometry
[8, 28]. PBMCwere removed from whole blood using Ficoll-
Hypaque and later were stained with a phycoerythrin-
labeled anti-CD14 (IgG2a; Dako, Japan) monoclonal
antibody to separate monocytes. These cells were fixed in
4% paraformaldehyde in phosphate-buffered saline for
15min at room temperature, permeabilized in 0.1% Triton
X-100 for 5min, incubated with 2mg/mL anti-BTK (48-2H)
or control IgG1 (Dako) monoclonal antibodies for 20min
on ice. Following this, they were washed and incubated again
with a 1:1000 dilution of fluorescein isothiocyanate-
conjugated goat antimouse IgG1 antibody (SouthernBio-
tech, Birmingham, AL) for 20min on ice. The stained cells
were analyzed by flow cytometry (Epics XL-MCL flow
cytometer, Beckman Coulter, Pasadena, CA).
Immunocytochemistry and confocal fluorescence
microscopy
Peripheral blood mononuclear cells were pipetted onto a
glass slide previously treated with acetic acid 2N and 70%
ethanol. Adherent cells were fixed in 4% paraformaldehyde
in PBS and 0.12M sucrose for 20min at room temperature.
For the process of permeabilization, cells were treated with
0.2% Triton X-100 in PBS for 20min.
Non-specific binding sites were blocked using 6% goat
serum. Cells were incubated overnight at 48C with
monoclonal anti-BTK (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), that recognizes the epitope at amino acid
positions 459-659 of the human BTK. Further, we used a
FITC-conjugated goat anti-mouse IgG1 as the secondary
antibody (SouthernBiotech – 1:1000). After extensiveT
ab
le
1.
C
lin
ic
al
an
d
la
bo
ra
to
ria
lc
ha
ra
ct
er
is
tic
s
of
X
-li
nk
ed
ag
am
m
ag
lo
bu
lin
em
ia
pa
tie
nt
s.
Pa
tie
nt
A
ge
(y
ea
rs
)
A
ge
at
on
se
t
A
ge
at
di
ag
no
si
sa
Fa
m
ily
hi
st
or
yb
Ig
le
ve
ls
at
di
ag
no
si
s
(m
g/
dL
)
C
D
19
þ
(%
)
BT
K
ex
pr
es
si
on
c
M
ut
at
io
ns
D
om
ai
n
Ig
G
Ig
M
Ig
A
N
uc
le
ot
id
e
Pr
ot
ei
n
X
LA
01
20
.6
7
4
y
6
y
þ
29
8
(7
50
–
17
80
)
6
(2
8–
21
2)
20
(9
0–
45
0)
0.
04
26
.3
0%
21
5G
>
T
R2
8L
PH
X
LA
02
24
.1
1
6
y
6
y
þ
18
0
(7
50
–
17
80
)
18
(2
8–
21
2)
22
(9
0–
45
0)
0.
30
25
.6
0%
19
70
G
>
A
G
61
3D
SH
1
X
LA
03
24
.7
6
6
y
6
y
þ
U
D
(7
50
–
17
80
)
U
D
(2
8–
21
2)
3
(9
0–
45
0)
0.
09
9.
00
%
25
1A
>
G
Y
40
C
PH
X
LA
04
6.
36
N
o
in
fe
ct
io
n
11
m
o
þ
12
6
(2
82
–
11
15
)
31
(4
0–
15
6)
18
(1
2–
10
4)
0.
14
no
t
te
st
ed
71
8C
>
T
Q
19
6X
TH
X
LA
05
9.
31
3
m
o
2y
8m
o
þ
14
9
(6
10
–
16
10
)
22
(2
9–
19
5)
1
(4
0–
28
9)
0.
30
39
.0
0%
63
10
4d
el
T
G
lu
34
8f
sX
55
SH
2
X
LA
06
13
.9
4
4
m
o
2
y
þ
86
(6
10
–
16
10
)
26
(2
9–
19
5)
23
(4
0–
28
9)
0.
10
4.
52
%
62
85
4_
62
85
5i
ns
T
Th
r3
24
fs
X
25
SH
2
X
LA
07
14
.8
0
N
o
in
fe
ct
io
n
1
y
6
m
o
þ
U
nr
eg
is
te
re
d
U
nr
eg
is
te
re
d
U
nr
eg
is
te
re
d
0.
09
3.
00
%
IV
S5
þ1
G
>
A
Ex
on
5
sk
ip
pi
ng
PH
X
LA
08
32
.0
2
2
y
8
y

54
(7
50
–
17
80
)
U
D
(2
8–
21
2)
U
D
(9
0–
45
0)
0.
10
13
.3
0%
16
34
T>
C
M
50
1T
SH
1
U
D
,
un
de
te
ct
ab
le
.
a
A
ge
at
th
e
st
ar
t
of
in
tr
av
en
ou
s
im
m
un
og
lo
bu
lin
re
pl
ac
em
en
t.
b
“
þ”
in
di
ca
te
s
th
at
bo
y(
s)
in
th
e
sa
m
e
fa
m
ily
di
ed
at
a
yo
un
g
ag
e
be
ca
us
e
of
in
fe
ct
io
n.
c N
or
m
al
ex
pr
es
si
on
is
>
95
%
.
M. A. Teocchi et al. Hyperexpression of monocyte XBP1 in XLA
© 2015 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. 173
washing with PBS, the coverslips were incubated with
Hoechst (Life Technologies) for visualization of the nucleus
and mounted on slides using Prolong Gold antifade (Life
Technologies). Images were generated in a confocal
fluorescence microscope (LSM - 510 Meta, ZEISS, Jena,
Germany) with a magnification of 63.
Statistical analysis
The GraphPad Prism 5 software for Windows (version 5.04)
was used for statistical analyses (San Diego, CA; www.
graphpad.com). Kruskal–Wallis and Dunn’s Multiple
Comparison tests were used to evaluate differences in the
BTK expression among three groups: XLA patients with
mutations that lead to a premature stop codon, XLA patients
with missense mutations, and healthy controls. Regarding
the expression of UPR-related genes, Mann–Whitney U test
was applied to assess significant differences between XLA
patients and controls. Statistical significance was determined
as P< 0.05.
Results
Stop codon or missense mutations were
identified in the XLA patients
Table 1 shows the nucleotide change which occurred in each
XLA patient and its consequences in the synthesis of the
protein.
Four patients had missense mutations, where the
substitution of one nucleotide (XLA01 215G>T, XLA02
1970G>A, XLA03 251A>G, and XLA08 1634T>C) leads
to an aminoacid replacement in the protein, without the
creation of a premature stop codon. However, these
missense mutations affect known and conserved residues
in BTK, with R28 being one of the most affected. In the PH
domain, this residue is essential for binding to phosphati-
dyl inositol, allowing the protein to reach the plasma
membrane [29]. Furthermore, in the PH domain, the
substitution of residue Y40 has implications for the
conformation of the loop between b strands and the
binding site with phosphatidyl inositol [30]. The residue
Table 2. List of reference and target genes.
Approved symbol Task Assay ID Approved name Synonyms
ATF4 UPR-related target Hs00909569_g1 Activating transcription factor 4 CREB-2, “tax-responsive enhancer element
B67“, TAXREB67
ATF6 UPR-related target Hs00232586_m1 Activating transcription factor 6 “Activating transcription factor 6 alpha,“
ATF6A
BAX UPR-related target Hs00180269_m1 BCL2-associated X protein BCL2L4
BCL2 UPR-related target Hs00608023_m1 B-cell CLL/lymphoma 2 Bcl-2, PPP1R50, “protein phosphatase 1,
regulatory subunit 50“
BTK XLA target Hs00163761_m1 Bruton agammaglobulinemia
tyrosine kinase
ATK, PSCTK1, XLA
CALR UPR-related target Hs00189032_m1 Calreticulin “Autoantigen Ro,“ cC1qR, CRT, FLJ26680,
RO, “Sicca syndrome antigen A
(autoantigen Ro; calreticulin),“ SSA
DDIT3 UPR-related target Hs01090850_m1 DNA-damage-inducible transcript 3 “C/EBP zeta,“ CHOP, CHOP10, GADD153
EIF2AK3 UPR-related target Hs00984006_m1 Eukaryotic translation initiation
factor 2-alpha kinase 3
PEK, PERK
EIF2S1 UPR-related target Hs00187953_m1 Eukaryotic translation initiation
factor 2, subunit 1 alpha, 35 kDa
EIF-2alpha, EIF2A
ERN1 UPR-related target Hs00176385_m1 Endoplasmic reticulum to nucleus
signaling 1
“Inositol-requiring enzyme 1,“ IRE1, IRE1P
GAPDH Reference gene Hs99999905_m1 Glyceraldehyde-3-phosphate
dehydrogenase
HPRT1 Reference gene Hs99999909_m1 Hypoxanthine
phosphoribosyltransferase 1
HGPRT, “Lesch-Nyhan syndrome“
HSPA5 UPR-related target Hs99999174_m1 Heat shock 70kDa protein 5
(glucose-regulated protein,
78 kDa)
BiP
HSP90B1 UPR-related target Hs00427665_g1 Heat shock protein 90 kDa beta
(Grp94), member 1
GP96, GRP94
IL6 Interleukin Hs00985639_m1 Interleukin 6 BSF2, HGF, HSF, IL-6, “interferon, beta 2“
XBP1 UPR-related target Hs00231936_m1 X-box binding protein 1
Gene names are in accordance with the approved symbol from the HUGO Gene Nomenclature Committee (HGNC) database.
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G613 is part of a structural assembly of functionally
important residues of the BTK kinase domain [31]. The
G613D mutation may prevent the interaction of this
domain with other BTK domains or with their substrates.
The M501T mutation also affects the kinase domain,
suggesting an interference with the enzymatic activity of
BTK.
In four patients, XLA04 to XLA07, we identified
premature terminations caused by nonsense mutation
(718C>T), frameshifts (63104delT and 62854_62855insT),
and a splice donor-site defect (IVS5þ1G>A).
Different BTK mutations lead to a specific
expression profile for BTK
A distinct pattern of BTK expression was observed in
patients with a premature stop codon and those with
missense mutations (Fig. 1). Specifically, patients with
mutations resulting in a premature stop codon exhibit
reduced expression of the BTK gene (P< 0.02, regardless of
the reference gene). However, missense mutations do not
affect BTK expression.
Absent or abnormal subcellular localization of
BTK protein in the cell cytoplasm
The monocyte BTK expression evaluated by flow cytom-
etry revealed a BTK deficiency (3.0–39.0%) in the seven
patients analyzed (Table 1). By immunocytochemistry, we
found that mutations in BTK lead to a lack of BTK protein
or nonfunctional protein synthesis, evidenced by abnormal
subcellular localization of BTK protein in the cell
cytoplasm (Fig. 2). The absence of functional BTK is
further confirmed by the very low levels of circulating B
lymphocytes observed in all patients studied (CD19þ
percentage; Table 1).
Increased expression of XBP1 in monocytes from
XLA patients
To elucidate the molecular features of UPR on XLA patients,
RT-qPCR analysis was performed on CD14þ cells isolated
from six patients with XLA and six healthy volunteers.
Among the 12 evaluated genes, the expression of XBP1 was
significantly higher (P¼ 0.0022) in XLA patients than in
healthy volunteers (Fig. 3). On the other hand, HSP90B1
expression was lower in XLA patients (P¼ 0.026).
Additionally, we also quantified IL6 expression. It is
known that sXBP1 induces IL6 secretion. We found an IL6
upregulation (P< 0.02, GAPDHþHPRT1 as the reference
gene) when patients (n¼ 7) were compared to controls
(n¼ 8). The patient labeled as XLA05 was excluded from this
RT-qPCR experiment because of the total consumption of
his RNA template.
Discussion
The definitive diagnosis of XLA is performed by sequencing
techniques since in 90–95% of cases, it is possible to identify
gene mutations in BTK [32].
According to our results, mutations in BTK that create a
premature stop codon (PTC) can be differentiated due to the
reduced level of BTK mRNA expression (Fig. 1). These
findings are explained by nonsense codons causing a
reduction in the mRNA level [33]. The nonsense-mediated
mRNA decay (NMD) is a surveillance pathway whose main
function is to reduce errors in gene expression by eliminating
mRNA transcripts that contain PTCs. According to the
literature, it is estimated that 30% of known mutations
associated with disease are because of mRNAs containing
PTCs [34].
At the protein level, flow cytometry assays revealed a
downregulation of BTK for all patients (Table 1). We also
Figure 1. Expression of BTK in PBMC from XLA patients and healthy controls. Relative expression of the BTK gene in XLA patients with mutations
that lead to a premature stop codon (XLA-SC; n¼ 4), XLA patients with missense mutations (XLA-M; n¼ 4), and controls (C; n¼ 8). The y-axis
represents the quantitative data of the relative mRNA expression of the BTK gene. Data from RT-qPCRs were generated from three reference genes:
GAPDH, HPRT1, and GAPDHþHPRT1 (in combination). Data are shown as median with interquartile range (whiskers: minimum to maximum).
Statistical analysis of the variance between the different groups was performed using the test of Kruskal–Wallis and Dunn's Multiple Comparison
test was used to compare all pairs of data (P< 0.05).
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found that mutations in BTK lead to a lack of BTK protein or
a nonfunctional protein synthesis, evidenced by abnormal
subcellular localization of BTK protein in the cell cytoplasm
(Fig. 2). In its active state, BTK is found close to the inner
surface of the plasma membrane. In fact, BTK phosphoryla-
tion is linked to membrane localization [35, 36].
Proteins which do not have the required conformation are
targets of the cellular mechanism which is designated
endoplasmic-reticulum-associated protein degradation
(ERAD). This mechanism retrotranslocates misfolded
proteins from the ER to the cytosol in order to be degraded
via the ubiquitin-proteasome (a protein-degrading com-
plex) [37]. Moreover, the increase of unfolded proteins in
the ER creates an imbalance between the demand and
capacity of the organelle, which is known as ER stress. This
triggers a network of signaling events collectively called UPR.
Since ER stress pathways have been implicated in
inflammatory diseases [14] but not yet studied in XLA
patients, we evaluated by RT-qPCR, the monocyte expres-
sion of 12 genes involved in UPR in XLA patients. These
genes encompass the three major ER stress branches: ERN1,
EIF2AK3, and ATF6, which mediate changes in gene
expression that characterize the UPR process [38]. In
general, we found a hyporegulation scenario for their
expressions but XPB1 had markedly upregulation (Fig. 3).
Accordingly, this significant monocyte XBP1 mRNA over-
expression immediately ex vivo could suggest that BTK
deficiency may produce ER stress. On the other hand, XBP1
can be expressed independently of the ER-stress response.
Toll-like receptor activation causes XBP1 splicing to
increase, XBP1 protein to rise, and pro-inflammatory
cytokine transcripts to be generated without initiating ER
stress responses. As BTK directly interacts with TLRs and
may inhibit TLR-induced cytokine production, as suggested
by Marron et al. [39], this might be one important
explanation for our observations (Fig. 3), which would
indicate that the increase inXBP1 transcripts in XLA patients
is independent of classical ER-stress response. Moreover,
downstream ER-stress target gene expressions, such as
HSPA5 and DDIT3, were not significantly altered in our
samples, which is evidence that the observed XBP1
overexpression may have occurred in the absence of a
classic ER-stress response.
There are no reports in the literature linking BTK and
XBP1. Our results prospectively uncover a new mechanism
for XBP1 and BTK in the innate immune system. Martinon
Figure 2. Immunolabeling of the BTK protein in PBMC (adherent
monocytes) from XLA patients and healthy controls. Immunocyto-
chemistry in PBMC from XLA patients with fluorescent labeling of BTK in
green (A, FITC), the cell nucleus in blue (B, Hoechst), and merged in C.
Mutations in BTK lead to a lack of BTK protein or nonfunctional protein
synthesis, evidenced by abnormal subcellular localization of BTK protein in
the cell cytoplasm. Patients XLA01, XLA02, XLA03, and XLA08 have
missense mutations. Patients XLA04, XLA05, XLA06, and XLA07 have
premature terminations caused by nonsense mutation. Original magnifi-
cation of 63x.
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et al. [25] demonstrated a new function of the IRE1-XBP1
pathway inmacrophages that is ER-stress independent. They
reported that TLR2 and TLR4 specifically activated XBP1
which amplifies TLR signaling by enhancing cytokine
production. Also, the IL6 overexpression found in our
XLA patients (Fig. 4) corroborates the suggestion of BTK
repressing TLR-induced cytokine production [39].
Iwakoshi et al. [40] demonstrated that sXBP1 induces
IL6 secretion, suggesting that, in addition to its important
role in UPR, sXBP1 regulates the expression of this
cytokine that is essential for plasma cell differentiation and
myeloma cell growth. The authors raised an interesting
hypothesis in which XBP1 has unidentified functions and
target genes that are unrelated to UPR, reinforced by the
fact that its role in driving the transcription of at least a
subset of ER chaperone genes is redundant [40]. Interleu-
kin 6 might be one such target. Our results also support
their hypothesis of the existence of a positive feedback loop
between IL6 and XBP1 (that would ensure high quantities
of both proteins during plasma cell differentiation). Since
plasma cell differentiation is defective in XLA patients, the
overexpression of both these genes could represent a
physiological attempt to correct this failure. In addition, as
IL6 is a potent pro-inflammatory cytokine and XBP1 a
multifunctional transcription factor, their involvement in
XLA physiopathology is conceivable and further studies
should be undertaken.
Before adequate immune globulin treatment, several
inflammatory conditions were described as being associated
with XLA. Recent data from 128 unique XLA patient
responses indicated that a considerable number of XLA
patients have symptoms that are consistent with a diagnosis
of arthritis, inflammatory bowel disease, or other inflam-
matory conditions [41]. The suggested positive feedback
loop between IL6 and XBP1 should be further investigated in
these patients.
Figure 3. Expression of ER stress sensor genes inmonocytes fromXLA patients and healthy controls. Relative expression of 12 genes associatedwithUPR
and the ER stress (see legend and Table 2) in XLA patients (XLA; n¼ 6) and healthy controls (C; n¼ 6). The y-axis represents the quantitative data of the
relative mRNA expression of genes. Data from RT-qPCRs were generated fromGAPDHþHPRT1 (in combination) as the reference gene. Data are shown
as median with interquartile range (whiskers: minimum to maximum). Statistical analyses of the variance between the two groups (C vs. XLA) were
performed using Mann–Whitney test (P< 0.05; P< 0.01).
Figure 4. Expression of IL6 in PBMC from XLA patients and healthy
controls. Relative expression of the IL6 gene in XLA patients (XLA; n¼ 7)
and controls (C; n¼ 8). The y-axis represents the quantitative data of the
relative mRNA expression of the IL6 gene. Data from RT-qPCRs were
generated from three reference genes: GAPDH, HPRT1, and the
combination of GAPDH and HPRT1 (shown as “Both” in the legend).
Data are shown as mean and SD. Statistical analysis of the difference
between the two groups was performed using the Mann–Whitney test
(*P< 0.05; **P< 0.01).
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In response to LPS, PBMC from XLA patients produced
significantly higher amounts of pro-inflammatory cytokines
and IL10 compared to controls, and this production was
influenced neither by the severity of the mutation nor the
affected domain [42]. The authors of this study also
demonstrated a predominantly inflammatory response in
XLA patients after LPS stimulation and suggested a
deregulation of TLR signaling in the absence of BTK.
Environmental factors were suggested to be involved in this
response [42].
Schmidt et al. [43] demonstrated that Btk is activated by
Tlr4 in primary macrophages and is required for normal
Tlr-induced Il10 production in multiple macrophage
populations. The authors suggest that the decreased Il10
production may be responsible for increased Il6. BTK also
plays a critical role in initiating TLR3 signaling. In the
absence of BTK, TLR3-induced phosphoinositide 3-kinase
(PI3K), AKT and MAPK signaling, activation of NFkB as
well as interferon regulatory factor 3 (IRF3), and AP-1
transcription factors were all defective. It was demonstrat-
ed that BTK directly phosphorylates TLR3 and, in
particular, the critical Tyr759 residue. Loss of BTK also
compromises the formation of the downstream TRIF/
receptor-interacting protein 1 (RIP1)/TBK1 complex [44].
Since some XLA patients develop enterovirus encephalitis
[45], the participation of a defective TLR3 signaling should
be considered as a potential molecular pathomecanism in
this condition.
Recently, Savic et al. [46] reported the first link between
TLR-dependent XBP1 activation and human inflammatory
disease. They showed that TLR-dependent XBP1 activation
is operative in the synovial fibroblasts (SF) of active
rheumatoid arthritis (RA) patients. They found that the
active (spliced) form of (s)XBP1 was significantly upregu-
lated in the active RA group compared to healthy controls
and patients in remission. Interestingly and paradoxically,
the expression of nine other ER stress response genes was
reduced in active RA compared to patients in remission,
suggestive of a UPR-independent process [46]. Our results
clearly suggest a similar scenario for XLA patients, who
experience autoimmune disease and BTK deficient mono-
cytes are known to be pro-inflammatory.
Moreover, the Savic et al. [46] study demonstrated that
sXBP1 was induced in SF by TLR2 and TLR4 stimulation,
resulting in sXBP1-dependent IL6 and TNF production.
Further studies are necessary to shed light on the mechanism
by which sXBP1 controls IL6 expression. Spliced XBP1
protein can confer on B cells the ability to produce IL6;
however, a comparison of wildtype and XBP1/ B cells
stimulated with LPS in vitro showed no significant difference
in IL6 production. Thus, XBP1 is not essential for expression
of IL6 [40] and it is well known that several transcription
factors, such as CCAAT/enhancer binding protein (C/EBP),
beta (CEBPB), and NFkB among others, regulate IL6
expression [47].
We also found a downregulation ofHSP90B1. The protein
encoded by this gene participates in the activation of
chaperones by the ATF6 and the immune response antigen
presentation by MHC class I pathways. There is evidence of
its involvement in some autoimmune and inflammatory
diseases [48]. More experiments could explain the role of the
monocyte HSP90B1 downregulation found in our XLA
patients; however, this result corroborates with the ruling
out of the participation of the ATF6 ER stress pathway in
these patients. Complementarily, monocyte ATF6 expres-
sion was not significantly different when XLA patients and
controls were compared (Fig. 3). Indeed, as stop codon BTK
mutations lead to an absence of the BTK protein, as seen in
Figure 2, an UPR activation in the affected cells is not
expected. On the other hand, we do not discard an
association of ER stress pathways when the BTK protein is
misfolded due to missense mutations. A larger or multi-
centric study including more patients could elucidate this
question.
Conclusions
Up to now, the literature has implied that BTK is critical for
B cell development and differentiation, but is also involved
in the regulation of other cell types, such as monocytes/
macrophages [49], neutrophils [50], and NK cells [51]. BTK
has also been implicated in TLR signaling and interacts with
TLR4, 6, 8, and 9 and also with MYD88, toll-interleukin 1
receptor (TIR) domain containing adaptor protein (TIRAP)
(also known as MyD88-adaptor-like protein [Mal]) and
interleukin-1 receptor-associated kinase 1 (IRAK1) [52],
indicating unexplored roles for this protein in innate and
adaptive immunity.
We demonstrated that BTK mRNA is markedly down-
regulated in XLA patients with stop codon mutations and
that missense mutations do not affect BTK expression.
Moreover, this is the first study relating XBP1 with BTK
mutations and XLA. Monocytes from XLA patients over-
express XBP1, a critical transcriptional factor for ER stress
and plasma cell differentiation. Our data suggest that
defective BTK might affect XBP1 expression in monocytes.
As a multifunctional transcriptional factor, our finding on
XBP1 upregulation in XLA patients opens several possible
avenues of research that will help us to understand the
complex pathophysiology in XLA.
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